Anchiano Therapeutics Ltd. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2018. For the quarter, the company reported operating loss was ILS 2,505,000 against ILS 1,902,000 a year ago. Loss before taxes on income was ILS 2,565,000 against ILS 1,868,000 a year ago. Net loss for the period was ILS 2,633,000 against ILS 1,925,000 a year ago. Basic and diluted loss was ILS 0.17 per share against ILS 0.2 per share a year ago. For the nine months, the company reported operating loss was ILS 10,068,000 against ILS 7,510,000 a year ago. Loss before taxes on income was ILS 11,009,000 against ILS 7,648,000 a year ago. Net loss for the period was ILS 11,470,000 against ILS 7,858,000 a year ago. Basic and diluted loss was ILS 0.98 per share against ILS 0.89 per share a year ago.